IMRN
OtherImmuron Ltd
Live · NASDAQ · May 9, Close
What's Moving IMRN Today?
No stock-specific AI insight has been generated for IMRN yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
IMRN News
20 articles- Presenting on Emerging Growth Conference 92 Day 2 on May 7; Register to live streamYahoo Finance·May 6, 2026
- Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00Yahoo Finance·Apr 22, 2026
- Immuron Double Digit 3Q Sales GrowthGlobeNewswire Inc.·Apr 17, 2026
- Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price TargetYahoo Finance·Mar 5, 2026
- Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps ConferenceYahoo Finance·Mar 5, 2026
- Immuron Reports HY26 Results and Strategic ResetYahoo Finance·Feb 25, 2026
- Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price TargetYahoo Finance·Jan 22, 2026
- Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live streamYahoo Finance·Jan 21, 2026
- Immuron Reports Continued Sales GrowthYahoo Finance·Jan 19, 2026
- Immuron (IMRN) Struggles After Announcing Trial ResultsYahoo Finance·Dec 15, 2025
- Immuron New U.S. Department of Defense Award & Clinical Trial UpdateYahoo Finance·Dec 3, 2025
- Immuron IMM-529 IND approved by FDAYahoo Finance·Nov 5, 2025
- Immuron Announces Clinical Trial UpdateYahoo Finance·Oct 31, 2025
- Presenting on Emerging Growth Conference 87 Day 1 on October 22. Register to live stream.Yahoo Finance·Oct 21, 2025
- Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price TargetYahoo Finance·Oct 17, 2025
- Immuron Q1 FY26 YoY growthYahoo Finance·Oct 13, 2025
- Immuron Submits IMM-529 IND to FDAYahoo Finance·Oct 8, 2025
- Immuron Letter to Shareholders – Projects UpdateYahoo Finance·Oct 2, 2025
- Immuron (IMRN) Posts 49% FY2025 Revenue Growth on Travelan SalesYahoo Finance·Sep 30, 2025
- Immuron Full Year 2025 Earnings: AU$0.023 loss per share (vs AU$0.03 loss in FY 2024)Yahoo Finance·Aug 31, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About Immuron Ltd
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.